Cagrilintide
Cagrilintide (AM833, NNC0174-0833)
Long-acting synthetic amylin analogue for weight management and type 2 diabetes. Works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking natural amylin hormone to regulate appetite, slow gastric emptying, and promote satiety.
Complete Dosing Guide
How to Take Cagrilintide
For Weight Management (Monotherapy)
Starting Dose:
- 0.3 mg subcutaneously once weekly for 4 weeks
- Note: This initial dose helps minimize gastrointestinal side effects
Dose Escalation Schedule:
- Week 1-4: 0.3 mg weekly
- Week 5-8: 0.6 mg weekly
- Week 9-12: 1.2 mg weekly
- Week 13-16: 2.4 mg weekly
- Week 17+: Continue 2.4 mg weekly (maintenance dose)
Alternative High-Dose Protocol (Research):
- Can escalate up to 4.5 mg weekly if tolerated
- Shown to be more effective than liraglutide 3.0 mg daily
How to Take It:
- Once-weekly subcutaneous injection
- Same day each week, with or without food
- Rotate injection sites (abdomen, thigh, upper arm)
For Combination Therapy (CagriSema)
Co-administration with Semaglutide:
- Both medications given as separate weekly injections
- Co-escalated together over 16-20 weeks
Dose Escalation Schedule:
- Week 1-4: Cagrilintide 0.25 mg + Semaglutide 0.25 mg
- Week 5-8: Cagrilintide 0.5 mg + Semaglutide 0.5 mg
- Week 9-12: Cagrilintide 1.0 mg + Semaglutide 1.0 mg
- Week 13-16: Cagrilintide 1.7 mg + Semaglutide 1.7 mg
- Week 17+: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Clinical Trial Results:
- CagriSema 2.4/2.4 mg: Average 20.4% weight loss at 68 weeks
- 60% of patients achieved ≥20% weight loss
- 23% achieved ≥30% weight loss
For Type 2 Diabetes
Dosing Protocol:
- Same escalation as weight management
- Target dose: 2.4 mg weekly
- Monitor blood glucose closely during titration
- May require diabetes medication adjustments
Dosing Calculators
Dose Calculator
Peptide amount must be greater than 0
Unit Converter
Quick Reference:
Milligrams:0
Micrograms (mcg):0
Grams:0
Kilograms:0
Ounces:0
Pounds:0
How to Take Cagrilintide
A. For Weight Management (Monotherapy)
Starting Dose:
0.3 mg subcutaneously once weekly for 4 weeks
Note: This initial dose helps minimize gastrointestinal side effects
Dose Escalation Schedule:
Week 1-4:0.3 mg weekly
Week 5-8:0.6 mg weekly
Week 9-12:1.2 mg weekly
Week 13-16:2.4 mg weekly
Week 17+:Continue 2.4 mg weekly (maintenance dose)
Alternative High-Dose Protocol (Research):
- Can escalate up to 4.5 mg weekly if tolerated
- Shown to be more effective than liraglutide 3.0 mg daily
How to Take It:
- Once-weekly subcutaneous injection
- Same day each week, with or without food
- Rotate injection sites (abdomen, thigh, upper arm)
B. For Combination Therapy (CagriSema)
Co-administration with Semaglutide:
- Both medications given as separate weekly injections
- Co-escalated together over 16-20 weeks
Dose Escalation Schedule:
Week 1-4:Cagrilintide 0.25 mg + Semaglutide 0.25 mg
Week 5-8:Cagrilintide 0.5 mg + Semaglutide 0.5 mg
Week 9-12:Cagrilintide 1.0 mg + Semaglutide 1.0 mg
Week 13-16:Cagrilintide 1.7 mg + Semaglutide 1.7 mg
Week 17+:Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Clinical Trial Results:
- CagriSema 2.4/2.4 mg: Average 20.4% weight loss at 68 weeks
- 60% of patients achieved ≥20% weight loss
- 23% achieved ≥30% weight loss
C. For Type 2 Diabetes
Dosing Protocol:
- Same escalation as weight management
- Target dose: 2.4 mg weekly
- Monitor blood glucose closely during titration
- May require diabetes medication adjustments
Dosing Calculators
Dose Calculator
Peptide amount must be greater than 0
Unit Converter
Quick Reference:
Milligrams:0
Micrograms (mcg):0
Grams:0
Kilograms:0
Ounces:0
Pounds:0
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.